JP2022017447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022017447A5 JP2022017447A5 JP2021179107A JP2021179107A JP2022017447A5 JP 2022017447 A5 JP2022017447 A5 JP 2022017447A5 JP 2021179107 A JP2021179107 A JP 2021179107A JP 2021179107 A JP2021179107 A JP 2021179107A JP 2022017447 A5 JP2022017447 A5 JP 2022017447A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- stereoisomers
- pharmaceutically acceptable
- syndrome
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 101001113278 Arabidopsis thaliana Probable serine/threonine-protein kinase PBL9 Proteins 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 108090000426 Caspase-1 Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 230000010799 Receptor Interactions Effects 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000024557 hepatobiliary disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000001016 myotrophic effect Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292202P | 2016-02-05 | 2016-02-05 | |
| US62/292,202 | 2016-02-05 | ||
| US201662341019P | 2016-05-24 | 2016-05-24 | |
| US62/341,019 | 2016-05-24 | ||
| US201662363775P | 2016-07-18 | 2016-07-18 | |
| US62/363,775 | 2016-07-18 | ||
| US201662385217P | 2016-09-08 | 2016-09-08 | |
| US62/385,217 | 2016-09-08 | ||
| US201662417219P | 2016-11-03 | 2016-11-03 | |
| US62/417,219 | 2016-11-03 | ||
| PCT/US2017/016509 WO2017136727A2 (en) | 2016-02-05 | 2017-02-03 | Compounds, compositions and methods |
| JP2018541178A JP6974331B2 (ja) | 2016-02-05 | 2017-02-03 | 化合物、組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541178A Division JP6974331B2 (ja) | 2016-02-05 | 2017-02-03 | 化合物、組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022017447A JP2022017447A (ja) | 2022-01-25 |
| JP2022017447A5 true JP2022017447A5 (enExample) | 2022-04-18 |
| JP7381543B2 JP7381543B2 (ja) | 2023-11-15 |
Family
ID=58054535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541178A Active JP6974331B2 (ja) | 2016-02-05 | 2017-02-03 | 化合物、組成物及び方法 |
| JP2021179107A Active JP7381543B2 (ja) | 2016-02-05 | 2021-11-02 | 化合物、組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541178A Active JP6974331B2 (ja) | 2016-02-05 | 2017-02-03 | 化合物、組成物及び方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9815850B2 (enExample) |
| EP (1) | EP3414239A2 (enExample) |
| JP (2) | JP6974331B2 (enExample) |
| KR (1) | KR102808827B1 (enExample) |
| CN (4) | CN118994191A (enExample) |
| AU (1) | AU2017213628B2 (enExample) |
| CA (1) | CA3012832A1 (enExample) |
| CL (1) | CL2018002081A1 (enExample) |
| CO (1) | CO2018008707A2 (enExample) |
| CR (1) | CR20180413A (enExample) |
| DO (1) | DOP2018000175A (enExample) |
| EA (1) | EA201891620A1 (enExample) |
| EC (1) | ECSP18066138A (enExample) |
| IL (2) | IL287136B2 (enExample) |
| MA (1) | MA44007A (enExample) |
| MX (3) | MX2018009448A (enExample) |
| MY (1) | MY196648A (enExample) |
| PH (1) | PH12018501583A1 (enExample) |
| SA (1) | SA518392146B1 (enExample) |
| SG (2) | SG10201913587WA (enExample) |
| TN (1) | TN2018000276A1 (enExample) |
| TW (2) | TWI781920B (enExample) |
| WO (1) | WO2017136727A2 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| MX380753B (es) | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| CN108200760B (zh) | 2015-07-22 | 2022-04-01 | 英安塔制药有限公司 | 作为rsv抑制剂的苯并二氮杂䓬衍生物 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| EP3402799B1 (en) | 2016-01-15 | 2022-05-04 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EA201891620A1 (ru) * | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| PE20190395A1 (es) | 2016-06-16 | 2019-03-13 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| AR110282A1 (es) * | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3582784B1 (en) | 2017-02-16 | 2022-06-08 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| AR112274A1 (es) | 2017-07-14 | 2019-10-09 | Hoffmann La Roche | Compuestos bicíclicos de cetona y sus métodos de uso |
| CN107759574B (zh) * | 2017-08-29 | 2020-07-03 | 南京药石科技股份有限公司 | 一种5-氟-1h-吡唑-3-甲酸酯中间体及其合成方法 |
| AU2018339068B2 (en) | 2017-09-29 | 2022-12-15 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| AU2018348930A1 (en) * | 2017-10-11 | 2020-03-26 | F. Hoffmann-La Roche Ag | Bicyclic compounds for use as RIP 1 kinase inhibitors |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| MX394621B (es) | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| EP3781571B1 (en) * | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| WO2019213445A1 (en) | 2018-05-03 | 2019-11-07 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| WO2020001420A1 (zh) * | 2018-06-26 | 2020-01-02 | 中国科学院上海有机化学研究所 | 一类细胞坏死抑制剂及其制备方法和用途 |
| WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
| FI3851436T3 (fi) | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| EP3670667A1 (en) * | 2018-12-19 | 2020-06-24 | Paris Sciences et Lettres - Quartier Latin | Identification of cognate pairs of ligands and receptors |
| TW202043229A (zh) | 2019-01-11 | 2020-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環酮化合物及其使用方法 |
| KR102769633B1 (ko) * | 2019-01-25 | 2025-02-19 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 아실아미노 가교된 헤테로사이클릭 화합물, 및 이의 조성물 및 응용 |
| PH12021552201A1 (en) | 2019-03-18 | 2022-05-30 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| CA3142360C (en) * | 2019-05-31 | 2023-11-14 | Medshine Discovery Inc. | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
| US12365695B2 (en) * | 2019-08-09 | 2025-07-22 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as RIPK1 inhibitors |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| CN114728958B (zh) | 2019-09-06 | 2025-05-02 | 里格尔药品股份有限公司 | Rip1抑制性化合物和制备与使用其的方法 |
| MX2022002718A (es) * | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos. |
| WO2021050672A1 (en) * | 2019-09-11 | 2021-03-18 | Ohio State Innovation Foundation | Kinase inhibitors for the treatment of neurodegenerative diseases |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| MX2022003984A (es) | 2019-10-04 | 2022-07-27 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| KR20250095767A (ko) * | 2019-11-07 | 2025-06-26 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
| WO2021108198A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| MX2022010693A (es) * | 2020-02-28 | 2022-09-26 | Univ Texas | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| WO2021211919A1 (en) * | 2020-04-17 | 2021-10-21 | Genzyme Corporation | Eclitasertib for use in treating conditions involving systemic hyperinflammatory response |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| TWI824259B (zh) * | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| CN116829571A (zh) | 2020-11-23 | 2023-09-29 | 英安塔制药有限公司 | 新型螺旋吡咯烷衍生的抗病毒药物 |
| CN114716427B (zh) * | 2021-01-07 | 2024-04-26 | 成都贝诺科成生物科技有限公司 | 一种作为rip抑制剂的化合物及其制备方法和用途 |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| WO2022171110A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof |
| US11945830B2 (en) | 2021-02-26 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AR125587A1 (es) * | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| JP7651929B2 (ja) | 2021-04-19 | 2025-03-27 | 住友ゴム工業株式会社 | ゴム組成物及びタイヤ |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| CN114989156B (zh) * | 2021-05-19 | 2024-07-05 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| AU2022328136A1 (en) | 2021-08-10 | 2023-11-30 | Abbvie Inc. | Nicotinamide ripk1 inhibitors |
| AU2022346718A1 (en) * | 2021-09-17 | 2024-03-28 | Bisichem Co., Ltd. | Fused heterocyclic rings as ripk1 inhibitors |
| TW202340182A (zh) | 2021-11-11 | 2023-10-16 | 美商健臻公司 | 做為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023119210A1 (ko) | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| EP4209213A1 (en) | 2022-01-05 | 2023-07-12 | Universität zu Köln | Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| CN116640156B (zh) * | 2022-02-22 | 2025-10-24 | 上海齐鲁制药研究中心有限公司 | Ripk1抑制剂 |
| WO2023174374A1 (zh) | 2022-03-16 | 2023-09-21 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2024170776A1 (en) | 2023-02-17 | 2024-08-22 | Universität Zu Köln | Triple kinase inhibition for the treatment of type i interferon response associated disorders |
| WO2025037940A1 (en) * | 2023-08-16 | 2025-02-20 | Bisichem Co., Ltd. | Pyrazole-1-carboxamides as rip1 kinase inhibitors |
| WO2025045253A1 (zh) * | 2023-08-31 | 2025-03-06 | 杭州百诚医药科技股份有限公司 | 苯并氮杂䓬酮类衍生物及其用途 |
| CN118084889B (zh) * | 2024-01-16 | 2024-09-27 | 宁夏医科大学 | 吲哚3-芳基-5-甲酰胺类衍生物及用途 |
| CN117849327A (zh) * | 2024-03-06 | 2024-04-09 | 军科正源（北京）药物研究有限责任公司 | 用于检测苏金单抗抗药性抗体的方法 |
| EP4652998A1 (en) | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US4477464A (en) | 1983-02-10 | 1984-10-16 | Ciba-Geigy Corporation | Hetero-benzazepine derivatives and their pharmaceutical use |
| EP0187037A3 (en) | 1984-12-21 | 1988-03-23 | Takeda Chemical Industries, Ltd. | Piperidine derivatives, their production and use |
| JPH035933Y2 (enExample) | 1987-08-04 | 1991-02-15 | ||
| EP0322779A3 (en) | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| JPH0256318A (ja) | 1988-08-19 | 1990-02-26 | Fujio Asai | 丸棒材の繰出しケース |
| JPH0295996A (ja) | 1988-10-03 | 1990-04-06 | Honda Motor Co Ltd | 鞍乗型車両 |
| JPH0334977A (ja) | 1989-06-29 | 1991-02-14 | Yoshitomi Pharmaceut Ind Ltd | イミダゾリルベンゾラクタム化合物 |
| NZ238576A (en) | 1990-06-18 | 1994-12-22 | Merck & Co Inc | Pyridinone derivatives, preparation and pharmaceutical compositions thereof |
| EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
| US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| US5206235A (en) | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
| US5457196A (en) | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| EP0534363B1 (en) | 1991-09-27 | 1997-07-09 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| JP3358069B2 (ja) | 1991-12-24 | 2002-12-16 | 武田薬品工業株式会社 | 三環性複素環類、その製造法及び剤 |
| US5484917A (en) | 1993-06-16 | 1996-01-16 | Pfizer Inc. | Substituted tetrahydrobenzazepinones |
| AU4282993A (en) | 1992-07-01 | 1994-01-31 | Pfizer Inc. | Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists |
| FI950842L (fi) | 1992-08-24 | 1995-02-23 | Merrell Dow Pharma | Enkefalinaasin inhibiittoreina käyttökelpoisia uusia 2-substituoituja trisyklisiä indaani-2-merkaptoasetyyliamidijohdannaisia |
| US5420271A (en) | 1992-08-24 | 1995-05-30 | Merrell Dow Pharmaceuticals, Inc. | 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase |
| US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| JPH07501085A (ja) | 1992-09-03 | 1995-02-02 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物 |
| US5583130A (en) | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5317017A (en) | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
| US5374721A (en) | 1992-10-14 | 1994-12-20 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| WO1994008683A1 (en) | 1992-10-16 | 1994-04-28 | Suprex Corporation | Automated supercritical fluid extraction |
| GB2272439A (en) | 1992-11-13 | 1994-05-18 | Merck & Co Inc | Benzo-fused lactams that inhibit the release of growth hormone |
| US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| GB9307833D0 (en) | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
| KR960702444A (ko) | 1993-05-13 | 1996-04-27 | 고야 마사시 | 3-아미노아제핀 화합물 및 그 의약 용도(3-aminoazepine compound and pharmaceutical use thereof) |
| US5430144A (en) | 1993-07-26 | 1995-07-04 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5606054A (en) | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
| AU697349B2 (en) | 1994-04-14 | 1998-10-01 | Glaxo Wellcome Inc. | CCK or gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
| JPH09512806A (ja) | 1994-05-07 | 1997-12-22 | ベーリンガー インゲルハイム コマンディトゲゼルシャフト | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物（ｉｉ） |
| IL114955A (en) | 1994-08-17 | 1999-12-22 | Novo Nordisk As | N-substituted naphthofused lactams and pharmaceutical compositions containing them |
| GB9420748D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9420747D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
| AU700404B2 (en) | 1994-11-17 | 1999-01-07 | Ciba Specialty Chemicals Holding Inc. | Monomers and composition which can be crosslinked and croslinked polymers |
| US5587375A (en) | 1995-02-17 | 1996-12-24 | Bristol-Myers Squibb Company | Azepinone compounds useful in the inhibition of ACE and NEP |
| US5691331A (en) | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
| ATE235472T1 (de) | 1995-06-07 | 2003-04-15 | Merck & Co Inc | N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide |
| US5726171A (en) | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
| US5700797A (en) | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| CO4750663A1 (es) | 1995-09-15 | 1999-03-31 | Sanofi Synthelabo | Derivados de quinolein-2 (1h)-ona, su preparacion y su aplicacion en terapeutica |
| WO1997024339A1 (en) | 1995-12-27 | 1997-07-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
| US5747235A (en) | 1996-01-26 | 1998-05-05 | Eastman Kodak Company | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity |
| JPH09295996A (ja) | 1996-03-06 | 1997-11-18 | Takeda Chem Ind Ltd | システインプロテアーゼ阻害化合物 |
| CZ59398A3 (cs) | 1996-06-29 | 1998-07-15 | Samjin Pharmaceutical Co., Ltd. | Piperazinové deriváty a způsob jejich přípravy |
| DE19638020A1 (de) | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| ATE346085T1 (de) | 1996-12-06 | 2006-12-15 | Vertex Pharma | Inhibitoren des interleukin-1-beta konvertierenden enzyms |
| JPH10251295A (ja) | 1997-03-07 | 1998-09-22 | Ono Pharmaceut Co Ltd | テトラゾール誘導体 |
| EP0994894A1 (en) | 1997-08-11 | 2000-04-26 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| US6211174B1 (en) | 1997-10-31 | 2001-04-03 | Merck & Co., Inc. | Naphtho-fused lactams promote release of growth hormone |
| FR2781483A1 (fr) | 1998-07-21 | 2000-01-28 | Hoechst Marion Roussel Inc | Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant |
| DE19858253A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
| JP2000256318A (ja) | 1999-03-02 | 2000-09-19 | Toa Eiyo Ltd | 縮合複素環誘導体、その製造法およびそれを含有する医薬品 |
| FR2803594B1 (fr) | 2000-01-11 | 2002-07-19 | Centre Nat Rech Scient | Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations |
| JP2003535046A (ja) | 2000-04-03 | 2003-11-25 | デュポン ファーマシューティカルズ カンパニー | Ａβタンパク質産生の阻害剤としての環状ラクタム |
| BR0110051A (pt) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer |
| AU2001255408A1 (en) | 2000-04-14 | 2001-10-30 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
| AU2001253692B2 (en) | 2000-04-24 | 2006-11-02 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
| WO2003031376A1 (en) | 2001-10-12 | 2003-04-17 | Aventis Pharmaceuticals Inc. | Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| CN1678586A (zh) * | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| EP1581520A4 (en) | 2002-12-13 | 2006-08-23 | Smithkline Beecham Corp | COMPOUNDS, COMPOSITIONS AND METHODS |
| US7288559B2 (en) | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| DE602004016992D1 (de) | 2003-05-02 | 2008-11-20 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| JP2005035933A (ja) | 2003-07-15 | 2005-02-10 | Takeda Chem Ind Ltd | 含窒素縮合複素環化合物の製造方法 |
| AU2004315596B2 (en) | 2003-08-29 | 2011-11-24 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
| MXPA06004006A (es) | 2003-10-10 | 2006-06-28 | Vertex Pharma | Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c. |
| WO2005056577A2 (en) | 2003-12-05 | 2005-06-23 | The Regents Of The University Of California | Peptide inhibitors of hiv |
| US20070010428A1 (en) | 2004-09-03 | 2007-01-11 | Mcmurray John S | Inhibitors of signal transduction and activator of transcription 3 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| AU2005295729B2 (en) * | 2004-10-13 | 2011-07-14 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| WO2006044449A2 (en) * | 2004-10-14 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| DE602005013275D1 (de) | 2004-12-02 | 2009-04-23 | Prosidion Ltd | Pyrrolopyridin-2-karbonsäureamide |
| US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| US20060217362A1 (en) | 2004-12-29 | 2006-09-28 | Tung Jay S | Novel compounds useful for bradykinin B1 receptor antagonism |
| WO2006079077A2 (en) | 2005-01-20 | 2006-07-27 | Acadia Pharmaceuticals Inc. | Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
| AU2006228426A1 (en) | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
| EP1874753A2 (en) | 2005-04-14 | 2008-01-09 | Smithkline Beecham Corporation | Compounds, compositions and methods |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20090240055A1 (en) | 2005-09-23 | 2009-09-24 | Krepski Larry R | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof |
| JP2009518399A (ja) | 2005-12-05 | 2009-05-07 | アフィニウム ファーマシューティカルズ， インク． | Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物 |
| CA2633500A1 (en) | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| CA2647949A1 (en) | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| JP2009543762A (ja) | 2006-06-09 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャネル遮断薬としてのベンゾアゼピノン |
| JP5468899B2 (ja) | 2006-07-20 | 2014-04-09 | アフィニウム ファーマシューティカルズ， インク． | Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 |
| ES2343481T3 (es) | 2006-07-21 | 2010-08-02 | Vertex Pharmaceuticals, Inc. | Antagonistas del receptor cgrp. |
| CA2665438C (en) | 2006-10-04 | 2014-12-02 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors |
| CA2675511A1 (en) * | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| US9562019B2 (en) | 2006-12-21 | 2017-02-07 | Sloan-Kettering Institute For Cancer Research | Substituted pyridazines as EGFR and/or KRAS inhibitors |
| CA2677331A1 (en) | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
| WO2008135525A2 (en) | 2007-05-02 | 2008-11-13 | Boehringer Ingelheim International Gmbh | Substituted azetidines, manufacturing and use thereof as medicaments |
| WO2008156580A1 (en) | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| CA2695244A1 (en) | 2007-08-03 | 2009-02-12 | Sanofi-Aventis | Caspase imaging probes |
| WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| JP4708443B2 (ja) | 2008-01-31 | 2011-06-22 | トヨタ自動車株式会社 | 作動制御マップおよび白線認識装置 |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト |
| WO2009103432A2 (en) | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| JP5699075B2 (ja) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ |
| US7884074B2 (en) | 2008-05-15 | 2011-02-08 | Ikaria Development Subsidiary Two, LLC | Compounds and methods for prevention and/or treatment of inflammation using the same |
| KR20110048491A (ko) | 2008-07-28 | 2011-05-11 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 스피로아미노디하이드로티아진 유도체들 |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| US8088890B2 (en) | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| US8293897B2 (en) | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
| WO2010077752A1 (en) | 2008-12-17 | 2010-07-08 | Merck Sharp & Dohme Corp. | Imidazolinone derivatives as cgrp receptor antagonists |
| WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
| US8624063B2 (en) | 2009-06-30 | 2014-01-07 | Wisconsin Alumni Research Foundation | Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing |
| BR112012005970A2 (pt) | 2009-09-16 | 2015-09-08 | Cylene Pharmaceuticals Inc | moduladores tricíclicos de proteína quinase |
| CA2779303A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| WO2011133964A2 (en) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| WO2011142381A1 (ja) | 2010-05-11 | 2011-11-17 | Fujita Takashi | ベンゾ若しくはピリドイミダゾール誘導体 |
| EP2575461A4 (en) | 2010-05-24 | 2013-12-18 | Univ Vanderbilt | SUBSTITUTED 6-METHYLNICOTINAMIDES USEFUL AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR5 |
| US9029501B2 (en) | 2010-11-02 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Method for making macrocycles |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013013826A1 (en) | 2011-07-27 | 2013-01-31 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| US20140357570A1 (en) | 2011-10-21 | 2014-12-04 | Massachusetts Eye And Ear Infirmary | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders |
| US9062002B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Substituted pyridine derivatives as FabI inhibitors |
| US9062075B2 (en) | 2011-12-02 | 2015-06-23 | Aurigene Discovery Technologies Limited | Tetrahydropyridine derivatives as FabI inhibitors |
| WO2013151739A1 (en) | 2012-04-03 | 2013-10-10 | 3M Innovative Properties Company | Crosslinkable composition comprising photobase generators |
| WO2013189241A1 (zh) | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| TWI520962B (zh) | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| US9611224B2 (en) | 2012-07-13 | 2017-04-04 | Hoffmann-La Roche Inc. | Antiproliferative benzo [B] azepin-2-ones |
| CN104470905B (zh) | 2012-08-09 | 2017-09-12 | 霍夫曼-拉罗奇有限公司 | 取代的杂‑氮杂*酮化合物 |
| CN103664904A (zh) | 2012-09-07 | 2014-03-26 | 李振 | 一种γ-分泌酶抑制剂及其用途 |
| WO2014072930A2 (en) | 2012-11-09 | 2014-05-15 | Aurigene Discovery Technologies Limited | Fused pyridine derivatives as antibacterial agents |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| FR3003860B1 (fr) | 2013-03-29 | 2015-11-27 | Oreal | Composes derives d'iridoides proteges ou non, composition les comprenant, utilisation comme colorant des fibres keratiniques et dispositifs |
| EP2986317A4 (en) | 2013-04-15 | 2016-10-05 | Yeda Res & Dev | INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| WO2015027137A1 (en) | 2013-08-23 | 2015-02-26 | University Of Tennessee Research Foundation | Improved synthesis of capuramycin and its analogues |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
| EP3148543B1 (en) | 2014-05-30 | 2020-04-08 | Icahn School of Medicine at Mount Sinai | Small molecule transcription modulators of bromodomains |
| US9616047B2 (en) | 2014-06-30 | 2017-04-11 | Regents Of University Of Minnesota | Inhibitors of beta-catenin in treatment of colorectal cancer |
| US20170226514A1 (en) | 2014-08-13 | 2017-08-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Prevention of tumour metastasis by inhibition of necroptosis |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| CN107108512B (zh) | 2014-10-10 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3017825A1 (en) | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
| EP3224237B1 (en) | 2014-12-24 | 2024-09-11 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| CN107108492B (zh) | 2014-12-24 | 2021-03-19 | 北京生命科学研究所 | 细胞坏死抑制剂 |
| EP3245198B1 (en) | 2015-01-13 | 2020-03-11 | Novartis AG | Pyrrolidine derivatives as angiotensin ii type 2 antagonists |
| CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX380753B (es) * | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| WO2017022962A1 (ko) | 2015-07-07 | 2017-02-09 | 가톨릭대학교 산학협력단 | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| EA201891620A1 (ru) * | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
-
2017
- 2017-02-03 EA EA201891620A patent/EA201891620A1/ru unknown
- 2017-02-03 JP JP2018541178A patent/JP6974331B2/ja active Active
- 2017-02-03 MA MA044007A patent/MA44007A/fr unknown
- 2017-02-03 TW TW106103687A patent/TWI781920B/zh active
- 2017-02-03 AU AU2017213628A patent/AU2017213628B2/en active Active
- 2017-02-03 IL IL287136A patent/IL287136B2/en unknown
- 2017-02-03 CA CA3012832A patent/CA3012832A1/en active Pending
- 2017-02-03 MX MX2018009448A patent/MX2018009448A/es unknown
- 2017-02-03 TW TW111140232A patent/TWI836679B/zh active
- 2017-02-03 US US15/424,216 patent/US9815850B2/en active Active
- 2017-02-03 KR KR1020187025396A patent/KR102808827B1/ko active Active
- 2017-02-03 CN CN202410933273.5A patent/CN118994191A/zh active Pending
- 2017-02-03 CN CN202210159353.0A patent/CN114437105B/zh active Active
- 2017-02-03 WO PCT/US2017/016509 patent/WO2017136727A2/en not_active Ceased
- 2017-02-03 CN CN201780021671.8A patent/CN109071504B/zh active Active
- 2017-02-03 SG SG10201913587WA patent/SG10201913587WA/en unknown
- 2017-02-03 CN CN202410933271.6A patent/CN118994190A/zh active Pending
- 2017-02-03 EP EP17705751.0A patent/EP3414239A2/en active Pending
- 2017-02-03 CR CR20180413A patent/CR20180413A/es unknown
- 2017-02-03 MY MYPI2018702604A patent/MY196648A/en unknown
- 2017-02-03 SG SG11201806302RA patent/SG11201806302RA/en unknown
- 2017-02-03 TN TNP/2018/000276A patent/TN2018000276A1/en unknown
- 2017-09-29 US US15/721,419 patent/US9896458B2/en active Active
- 2017-09-29 US US15/721,470 patent/US10131676B2/en active Active
-
2018
- 2018-07-19 IL IL260674A patent/IL260674B/en unknown
- 2018-07-25 PH PH12018501583A patent/PH12018501583A1/en unknown
- 2018-08-01 DO DO2018000175A patent/DOP2018000175A/es unknown
- 2018-08-02 MX MX2021013228A patent/MX2021013228A/es unknown
- 2018-08-02 SA SA518392146A patent/SA518392146B1/ar unknown
- 2018-08-02 CL CL2018002081A patent/CL2018002081A1/es unknown
- 2018-08-02 MX MX2021013226A patent/MX2021013226A/es unknown
- 2018-08-21 CO CONC2018/0008707A patent/CO2018008707A2/es unknown
- 2018-09-03 EC ECSENADI201866138A patent/ECSP18066138A/es unknown
- 2018-09-13 US US16/130,817 patent/US10604535B2/en active Active
-
2020
- 2020-02-05 US US16/782,446 patent/US20200317691A1/en not_active Abandoned
-
2021
- 2021-02-25 US US17/185,684 patent/US20230043400A1/en not_active Abandoned
- 2021-11-02 JP JP2021179107A patent/JP7381543B2/ja active Active
-
2023
- 2023-08-10 US US18/232,435 patent/US12358928B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017447A5 (enExample) | ||
| JP2024166311A (ja) | 化合物、組成物、及び、方法 | |
| JP2022530985A (ja) | 炎症性疾患または望ましくない免疫応答に関連する疾患の治療におけるイタコン酸誘導体およびその使用 | |
| JP2024086819A (ja) | 化合物、組成物、及び、方法 | |
| JP2019508407A5 (enExample) | ||
| CN1675177A (zh) | 莫达非尼多晶型 | |
| JP5063600B2 (ja) | ピリダジノ［４，５−ｂ］インドール誘導体の新規な結晶形 | |
| RS59599B1 (sr) | Formulacije tableta neratinib maleata | |
| JP6101789B2 (ja) | Ａｌｘ受容体アゴニストとしてのフッ素化架橋スピロ［２．４］ヘプタン誘導体 | |
| JP2024161449A (ja) | ヤヌスキナーゼ阻害剤の結晶形 | |
| JP2024500101A (ja) | 化合物の固体形態 | |
| JP2021073256A5 (enExample) | ||
| US20200113910A1 (en) | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases | |
| JP2013520488A (ja) | ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法 | |
| US6294540B1 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| JPWO2021130492A5 (enExample) | ||
| CN115768754B (zh) | 调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物 | |
| JP6330038B2 (ja) | Ａｌｘ受容体アゴニストとしてのピペラジン置換架橋スピロ［２．４］ヘプタン誘導体 | |
| CN120731207A (zh) | 6-烷氧基吡唑并嘧啶化合物及其药学用途 | |
| AU2024226032A1 (en) | Substituted pyrazolopyrimidine compounds and medical use thereof | |
| JP6407268B2 (ja) | Ａｌｘ受容体アゴニストとしてのジフルオロエチル−オキサゾール置換架橋スピロ［２．４］ヘプタン誘導体 | |
| JP6775009B2 (ja) | ３−ビシクロ［３．２．０］ヘプ−３−エン−６オンエンの鏡像異性体の分離 | |
| WO2013147216A1 (ja) | （２－ヘテロアリールアミノ）コハク酸誘導体 | |
| JP2009520000A (ja) | カンナビノイドｃｂ１受容体モジュレーターとしての４，５−ジヒドロ−（１ｈ）−ピラゾール誘導体 | |
| EP2899193B1 (en) | Crystalline form of abacavir that is essentially free of solvent |